Regeneron Pharmaceuticals, Inc. (REGN) insider have most recently took part in a trading activity. On Aug 25, 2017 Sanofi, 10% Owner bought 72,378 shares having total worth of $34,839,874 at the price of $481.36 per share, following the transaction a total of 23,880,537 shares owned by Sanofi. Before this latest buy, Sanofi purchased REGN at 3 other times during the past twelve months, for a total investment of $1773.64M at an average of $442.94 per share.
The stock has experienced a total of 15 insider trades in the past three months. These trades include 13 sell activities and 2 buy trades. Furthermore, over the past 12 months , the stock was traded 22 times by insiders. In 19 of these trades, the insider was a seller while an employee of the company was the buyer in 3 instances.
|Time Frame||Number of Insider Buy||Number of Insider Sell||Stock Price Change(%)|
Shares of Regeneron Pharmaceuticals, Inc. (REGN) traded up 0.3% on Aug 28, 2017, hitting $479.22. 831,240 shares of the company’s stock traded hands. Regeneron Pharmaceuticals, Inc. has a 52 week low of $331.05 and a 52 week high of $526.53. The company’s market cap is $44,380 million.
Regeneron Pharmaceuticals, Inc. (REGN) last announced its earnings results on Aug 3, 2017. The company reported 4.17 earnings per share (EPS) for the quarter, higher than the consensus estimate of 3.16 by $1.01. The company had revenue of $1,470 million for the quarter, compared to the consensus estimate of $1,350 million. During the same quarter in the previous year, the company posted 2.82 earnings per share. The company’s revenue for the quarter was up 21% on a year-over-year basis.
|earnings per share||4.17||2.92||3.04||3.13||2.82||2.57||2.83||3.47||2.89||2.79|
Regeneron Pharmaceuticals, Inc. has been the subject of a number of recent research reports. Analysts at Morgan Stanley Maintains shares of Regeneron Pharmaceuticals, Inc. to an Equal-Weight rating in a research note. They now have a $450.00 price target on the stock.
Regeneron Pharmaceuticals, Inc. is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.The Company was incorporated in January 1988 in the State of New York. The Company currently has two marketed products: EYLEA (aflibercept) Injection, known in the scientific literature as VEGF Trap-Eye, which is available in the United States for the treatment of neovascular age-related macular degeneration (wet AMD). Wet AMD is the main cause of acquired blindness for people over the age of 65 in the United States and Europe; and ARCALYST (rilonacept) Injection for Subcutaneous Use, which is available by prescription in the United States for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older. The Company has 13 product candidates in clinical development, all of which were discovered in its research laboratories. Its Trap-based, late-stage programs are: EYLEA, which is being developed for the treatment of additional serious eye diseases; ZALTRAP (aflibercept), known in the scientific literature as VEGF Trap, which is being developed in oncology in collaboration with Sanofi; and ARCALYST, which is being developed for the prevention of gout flares in patients initiating uric acid-lowering treatment. The Company, together with its ex-U.S. collaborator Bayer HealthCare, is evaluating EYLEA in Phase 3 programs in patients with central retinal vein occlusion (CRVO), diabetic macular edema (DME), and choroidal neovascularisation (CNV) of the retina as a result of pathologic myopia. The Company’s preclinical research programs are in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The Company’s manufacturing facilities are located in Rensselaer, New York and consist of three buildings totaling approximately 395,000 square feet of research, manufacturing, office, and warehouse space. It currently has approximately 54,000 liters of cell culture capacity at these facilities. It faces competition from pharmaceutical, biotechnology, and chemical companies. The Company’s competitors are Genentech, Novartis, Pfizer Inc., Bayer HealthCare, Onyx Pharmaceuticals, Inc., Eli Lilly and Company, Abbott, sanofi-aventis, Merck & Co., Amgen Inc., Roche, and others. Its present and future business would be subject to regulation under the United States Atomic Energy Act, the Clean Air Act, the Clean Water Act, the Comprehensive Environmental Response, Compensation and Liability Act, the National Environmental Policy Act, the Toxic Substances Control Act, the Resource Conservation and Recovery Act, national restrictions, and other current an
Latest posts by William White (see all)
- Insider Trading Review: FS Investment Corporation $FSIC - January 13, 2018
- Insider Trader Watch: ENERTOPIA CORP $ENRT - January 13, 2018
- Insider Trading in Focus: Swiss Helvetia Fund, Inc. (The) $SWZ - January 13, 2018